A Study of Dose Titration of LY2189265 in Overweight Patients With Type 2 Diabetes Mellitus (EGO)
This study has been completed.
Sponsor:
Eli Lilly and Company
Information provided by:
Eli Lilly and Company
ClinicalTrials.gov Identifier:
NCT00630825
First received: February 28, 2008
Last updated: December 9, 2009
Last verified: December 2009
- Full Text View
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Purpose
To study once weekly injections of LY2189265 compared to placebo on blood glucose by measuring HbA1C change from baseline after 16 weeks in overweight Type 2 Diabetes Mellitus Patients.
| Condition | Intervention | Phase |
|---|---|---|
|
Diabetes Mellitus Type 2 |
Drug: Placebo Drug: LY2189265 |
Phase 2 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Caregiver, Investigator) Primary Purpose: Treatment |
| Official Title: | The Effect of Dose Titration of LY2189265 in Overweight and Obese Patients With Type 2 Diabetes Mellitus |
Resource links provided by NLM:
Further study details as provided by Eli Lilly and Company:
Primary Outcome Measures:
- Evaluate once weekly injections of LY2189265 (adjusted and non-adjusted doses) compared to placebo on blood glucose as measured by HbA1C change from baseline in overweight patients with Type 2 Diabetes Mellitus [ Time Frame: at 16 weeks ] [ Designated as safety issue: Yes ]
Secondary Outcome Measures:
- Fasting blood glucose [ Time Frame: baseline and 16 weeks ] [ Designated as safety issue: Yes ]
- Meal test glucose excursion (change in blood glucose to test meal) [ Time Frame: baseline and 16 weeks ] [ Designated as safety issue: Yes ]
- Self-monitoring of blood glucose (SMBG) 8-point profile [ Time Frame: 2 separate days in weeks preceeding baseline visit, week 4, week 8, and at 16 weeks. ] [ Designated as safety issue: Yes ]
- Body weight and waist circumference [ Time Frame: weight at every clinic visit and waist at baseline and week 16 ] [ Designated as safety issue: Yes ]
- B-cell function and insulin sensitivity as estimated by the updated Homeostasis Model Assessment tool (HOMA2) [ Time Frame: baseline and at 16 weeks ] [ Designated as safety issue: Yes ]
- Percentage of Patients achieving an HbA1C of < 7% and <, equal to 6.5% [ Time Frame: baseline, week 4,8, and 16 weeks ] [ Designated as safety issue: No ]
- Evaluate safety/tolerability of LY2189265 compared to placebo; Evaluate symptoms of nausea,vomiting,diarrhea,dyspepsia measured by Visual Analog Scale and Gastroparesis Cardinal Symptom Index questionnaire; Evaluate hypoglycemia, hyperglycemia,lipids [ Time Frame: baseline, week 4,8, and 16 ] [ Designated as safety issue: Yes ]
- To characterize the pharmacokinetics (PK) of LY2189265 and the relationship between LY2189265 exposure and safety measures. [ Time Frame: week 4,8,and 16 ] [ Designated as safety issue: Yes ]
- To measure and evaluate patient perception of medication effectiveness using the Perceptions about Medications - Diabetes (PAM-D-S) questionnaire. [ Time Frame: baseline, week 4,8, and 16 ] [ Designated as safety issue: Yes ]
- To test the psychometric properties of the PAM-D-S and to validate its use for future clinical trials. [ Time Frame: baseline, week 4,8 and 16 ] [ Designated as safety issue: Yes ]
| Enrollment: | 266 |
| Study Start Date: | April 2008 |
| Study Completion Date: | January 2009 |
| Primary Completion Date: | January 2009 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Placebo Comparator: 1
One weekly subcutaneous placebo injection
|
Drug: Placebo
once weekly placebo injection subcutaneously
|
|
Experimental: 2
0.5/1.0 mg arm: one weekly subcutaneous injection- 0.5 mg for 4 weeks, followed by once weekly subcutaneous injection of 1.0 mg for 12 weeks.
|
Drug: LY2189265
0.5 to 1.0 mg once weekly subcutaneous injection - 0.5 mg for 4 weeks, followed by once weekly subcutaneous injection 1.0 mg for 12 weeks.
|
|
Experimental: 3
1.0 mg arm: once weekly subcutaneous injections 1.0 mg for 16 weeks.
|
Drug: LY2189265
1.0 mg subcutaneously weekly injection for 16 weeks
|
|
Experimental: 4
1.0 to 2.0 mg arm: once weekly subcutaneous injections of 1.0 mg for 4 weeks, followed by once weekly subcutaneous injections of 2.0 mg for 12 weeks.
|
Drug: LY2189265
1.0 mg subcutaneous injection weekly for 4 weeks followed by 2.0 mg weekly subcutaneous injection for 12 weeks.
|
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Type 2 Diabetes Mellitus > 3 months by history prior to entering the trial,based on disease diagnostic criteria from the ADA.
- Men or women age 18 or older. Women must have negative pregnancy test and be willing to use birth control during study duration and one month post.
- Have HbA1C of > 7.0 to < or equal to 10.5% as determined by central laboratory at visit one.
- Have a BMI (body mass index) between 27 and 40 kg/m2, inclusive.
- Been on same doses for 3 months of any approved combination of 2 oral antihyperglycemic medications in any combination of the following: sulfonylureas (e.g. Chlorpropamide or Diabinase, Glimepiride or Amaryl, Tolbutamide or Orinase, Tolazamide or Tolinase, Glipizide or Glucotrol, Glyburide also know as Micronase, Diabeta, or Glynase), biguanides (e.g. Glucophage or metformin), thiazolidinediones (e.g. Rosiglitazone or Avandia, or Pioglitazone or Actos), or DPP-IV inhibitors (e.g. Sitagliptin or Januvia). A combination pill of any 2 of these drugs is allowed (1 only),(e.g. Metformin and Glipizide or Metaglip),(e.g. Metformin and Glyburide or Glucovance), (e.g. Pioglitazone and Glimepiride or Duetact), or (e.g. Sitagliptin and Metformin or Janumet).
Exclusion Criteria:
- Have known Type 1 Diabetes Mellitus
- Have taken GLP-1 or any GLP-1 analog drug (Byetta)
- Have a history of unstable angina, heart attack (myocardial infarction), heart arrhythmia (ventricular), congestive heart failure, or other coronary intervention (PTCA, open heart surgery, or CABG), a transient ischemic attack (TIA) or stroke (cerebrovascular accident) in the last 6 months prior to visit 1.
- Have acute or chronic hepatitis or elevated liver function tests (ALT), a history of chronic or recurrent pancreatitis. Have renal disease or a serum creatinine (blood test) > 2mg/dL. If taking biguanides (e.g. metformin or Glucophage), or DPP-IV inhibitors (e.g. Sitagliptin or Januvia or Janumet), creatinine must be < than or equal to 1.5 mg/dL.
- Currently taking prescription or over the counter medications to prevent weight loss (alli).
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00630825
Hide Study Locations
Hide Study LocationsLocations
| United States, Arizona | |
| For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | |
| Peoria, Arizona, United States, 85381 | |
| United States, California | |
| For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | |
| Anaheim, California, United States, 92805 | |
| For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | |
| Lancaster, California, United States, 93534 | |
| For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | |
| Northridge, California, United States, 91326 | |
| For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | |
| Palm Springs, California, United States, 92262 | |
| United States, Florida | |
| For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | |
| South Miami, Florida, United States, 33143 | |
| For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | |
| West Palm Beach, Florida, United States, 33401 | |
| United States, Georgia | |
| For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | |
| Athens, Georgia, United States, 30606 | |
| For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | |
| Atlanta, Georgia, United States, 30303 | |
| United States, Illinois | |
| For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | |
| Springfield, Illinois, United States, 62704 | |
| United States, Indiana | |
| For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | |
| Indianapolis, Indiana, United States, 46250 | |
| United States, Maine | |
| For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | |
| Biddeford, Maine, United States, 04005 | |
| United States, Michigan | |
| For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | |
| Ann Arbor, Michigan, United States, 48108 | |
| For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | |
| Bloomfield Hills, Michigan, United States, 48302 | |
| United States, Missouri | |
| For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | |
| St Louis, Missouri, United States, 63141 | |
| United States, Montana | |
| For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | |
| Billings, Montana, United States, 59101 | |
| United States, New Jersey | |
| For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | |
| Flemington, New Jersey, United States, 08822 | |
| United States, New York | |
| For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | |
| Syracuse, New York, United States, 13210 | |
| United States, North Carolina | |
| For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | |
| Greensboro, North Carolina, United States, 27401 | |
| For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | |
| Greenville, North Carolina, United States, 27834 | |
| For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | |
| Morehead City, North Carolina, United States, 28557 | |
| United States, Tennessee | |
| For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | |
| Memphis, Tennessee, United States, 38119 | |
| United States, Texas | |
| For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | |
| Austin, Texas, United States, 78731 | |
| For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | |
| Dallas, Texas, United States, 75230 | |
| For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | |
| San Antonio, Texas, United States, 78237 | |
| United States, Virginia | |
| For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | |
| Norfolk, Virginia, United States, 23510 | |
| United States, Washington | |
| For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | |
| Renton, Washington, United States, 98057 | |
| For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | |
| Spokane, Washington, United States, 99216 | |
| For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | |
| Tacoma, Washington, United States, 98405 | |
| For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | |
| Wenatchee, Washington, United States, 98801 | |
| United States, Wisconsin | |
| For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | |
| Menomonee Falls, Wisconsin, United States, 53051 | |
| Puerto Rico | |
| For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | |
| Manatí, Puerto Rico, 00674 | |
| For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | |
| San Juan, Puerto Rico, 00907 | |
| For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | |
| Toa Baja, Puerto Rico, 00949 | |
Sponsors and Collaborators
Eli Lilly and Company
Investigators
| Study Director: | Call 1-877-CTLILLY (1-877-285-4559) Mon-Fri 9AM-5PM Eastern time (UTC/GMT - 5 hours, EST) | Eli Lilly and Company |
More Information
Additional Information:
No publications provided
| Responsible Party: | Chief Medical Officer, Eli Lilly |
| ClinicalTrials.gov Identifier: | NCT00630825 History of Changes |
| Other Study ID Numbers: | 12068, H9X-MC-GBCJ |
| Study First Received: | February 28, 2008 |
| Last Updated: | December 9, 2009 |
| Health Authority: | United States: Food and Drug Administration |
Additional relevant MeSH terms:
|
Diabetes Mellitus Diabetes Mellitus, Type 2 Overweight Glucose Metabolism Disorders |
Metabolic Diseases Endocrine System Diseases Body Weight Signs and Symptoms |
ClinicalTrials.gov processed this record on May 22, 2013